+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Expired

The Harrington Prize for Innovation in Medicine

Harrington Discovery Institute

The Harrington Prize for Innovation in Medicine, presented by the American Society for Clinical Investigation and Harrington Discovery Institute, honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and potential for clinical application. Each year one Harrington Prize recipient is chosen. The prize includes:

An unrestricted $20,000 honorarium
The Harrington Prize Lecture, delivered at the AAP-ASCI-APSA Joint Meeting
Participation in the Harrington Discovery Institute Scientific Symposium
A personal essay, published in the Journal of Clinical Investigation

AI Based Application Success Predictor

The Harrington Discovery Institute (HDI), part of the Harrington Project for Discovery & Development (launched in 2012), operates out of Cleveland and supports scientific innovation across the US, UK, and Canada. Its mission is to de-risk early-stage therapeutic discoveries emerging from academic labs and fast-track them toward commercialization and clinical use. It achieves this through strategic funding, expert project management, and partnerships with both philanthropic and industry entities.

Key Performance Metrics:

214 therapeutics in progress

74 institutions supported

43 company spin-outs

21 clinical-stage programs

15 licensing deals with pharmaceutical partners

Success Predictors: What Makes HDI Powerful

1. Comprehensive Scholar-Innovator Support Model

HDI selects physician-scientists or researcher innovators early in their careers and provides them with:

Grant funding

Drug development and commercialization guidance

Access to strategic investors and partnerships

Scholars often become eligible for:

Acceleration grants (up to $300,000)

Mission-aligned investment funds (up to $2 million)

2. Structured Translational Pathway

HDI embeds funded scientists into a Therapeutics Development Center staffed with project managers, business development experts, and pharma veterans—creating a seamless transition from science to market-ready medicine.

3. Tangible Outcomes

The institute’s model has led to:

Multiple academic drug projects progressing into drug development companies and/or pharma licensing

Success stories across rare diseases, major medical conditions, and brain health (e.g., partnerships with Takeda, Allyx Therapeutics spin-out)

4. Rapid Response Capabilities

In crises like the COVID-19 pandemic, HDI rapidly awarded grants to 12 projects across multiple institutions, advancing vaccine candidates, broad-spectrum antivirals, and therapeutics—with several agents reaching clinical or IND-enabling stages.

5. Synergistic Philanthropy & Recognition

HDI’s Morgan Stanley GIFT Cures initiative and partnerships have garnered philanthropy awards (e.g., Synergy for Change, 2025), reinforcing its role as a philanthropic innovation leader.

Summary Table: HDI as a Predictor of Success

Component	Why It Predicts Future Success
Scholar-Innovator Program	Combines funding with drug dev expertise and access to commercialization resources
Therapeutics Development Center	Embeds academic projects within a drug development engine—de-risking early phases
Proven Translational Outcomes	Strong record of moving discoveries into preclinical, clinical, and market stages
Crisis-focused Initiatives	Demonstrated ability to rapidly respond to global health emergencies
Strategic Philanthropic Partnerships	Amplifies scale and sustainability through collaborative funding models

Featured Success Stories

2025 Scholar Class includes ten physician-scientists targeting diseases from rare genetic disorders (e.g., Alagille Syndrome, SSADHD) to antibiotic resistance and autoimmune therapies.

2022 Scholar-Innovators focused on pulmonary diseases, spinal cord injury, COVID-19, corneal diseases, hepatitis, and cancers—demonstrating breadth of impact.

Rare Disease & Brain Health Centers at HDI have spun out companies (like Allyx Therapeutics) and secured deals with major pharmaceutical companies (e.g., Takeda).

2015 ADDF-Harrington Collaboration backed projects in Alzheimer’s that would have likely struggled to find support—underscoring HDI’s catalytic role in high-risk, high-reward research.

In Summary

The Harrington Discovery Institute serves as a proven indicator of future research and commercialization success. By combining financial backing, expert drug development support, and structured investment access, HDI consistently propels academic discoveries toward impactful therapies and patient benefit.

Specialties

Public Health

Eligibility Requirements

MD or MD/PhD (or equivalent)
Does not need to be an ASCI member
No age or citizenship requirement
Self-nomination is not permitted
Must be available to deliver a lecture at the AAP-ASCI-APSA Joint Meeting
Must be available to participate in Harrington Discovery Institute Scientific Symposium
Must submit a personal essay for publication in the Journal of Clinical Investigation

Sponsor Details

Sponsor Institute/Organizations: Harrington Discovery Institute

Sponsor Type: Corporate/Non-Profit

Address: 11407 Euclid Ave. Floor 2 Cleveland, OH 44106 United States

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity